PostEra
YC W20Boston, US · Founded 2019 · Delaware corporation · 40 employees · 6 known investors
Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies. The platform combines machine learning, medicinal chemistry, and software engineering to improve the drug development process.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesAI-powered Drug DiscoveryMachine LearningCOVID-19United States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (W20)
PostEra was founded in 2019 by Aaron Morris, Alpha Lee, and Matthew Robinson.
AM
Aaron MorrisinCEO & Co-FounderAaron Morris is founder and CEO of PostEra, which applies artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies.
AL
Alpha LeeinFounder
MR
Matthew RobinsoninFounder
Investors · 6
Reported raises · per SEC filings
Form D private placements$26.1M disclosed across 1 of 2 rounds · 2021–2025
▶$26.1MraisedJan 2022 · 21 investors · BiotechnologyRule 506(b)
▶$26.1MraisedJan 2022 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew RobinsonExecutive Officer, Director
- Alpha LeeExecutive Officer, Director
- Aaron MorrisExecutive Officer, Director
- Offering amount
- $27.5M
- Amount sold
- $26.1M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Images
Competitors · 2
by search overlap
Prothena6 shared keywordsProthena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.
Ideaya Biosciences5 shared keywordsIDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
Companies competing with PostEra for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does PostEra do?
- Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies. The platform combines machine learning, medicinal chemistry, and software engineering to improve the drug development process.
- Who founded PostEra?
- PostEra was founded by Aaron Morris, Alpha Lee, Matthew Robinson in 2019.
- Who are PostEra's investors?
- PostEra's investors include Breyer Capital, HOF Capital, Lifeforce Capital, Metaplanet, Y Combinator, ACE & Company.
- How much funding has PostEra raised?
- PostEra has disclosed $26.1M raised across 1 of its 2 known rounds.
- Where is PostEra headquartered?
- PostEra is headquartered in Boston, US.